DiaMedica Therapeutics宣布首批患者入组Dm199治疗胎儿生长受限的二期临床试验

美股速递
Jun 23

DiaMedica Therapeutics Inc. 已启动其针对胎儿生长受限(FGR)的潜在疗法Dm199的二期临床试验,并为首批患者完成了给药。这项进展标志着该候选药物在临床开发路径上迈出了关键一步,旨在解决这一目前缺乏有效药物治疗的严重妊娠并发症。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10